As a related report to this result, using tiragolumab (anti-TIGIT antibody) plus atezolizumab for the treatment of advanced or metastatic NSCLC with strong PD-L1 expression does not meet its co-primary endpoint of PFS (phase III SKYSCRAPER-01 study)25. Here, TIGIT is linked to non-small cell lung carcinoma.